Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R130 in Relapsed/Refractory Cervical and Endometrial Cancer
NCT05812677Phase 1Recruiting
- Sponsor
- Shanghai Yunying Medical Technology Co., Ltd.
- Start
- Feb 2023
- Primary completion
- Feb 2025
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of R130 in Cervical Cancer (CC) and endometrial cancer (EC), sponsored by Shanghai Yunying Medical Technology Co., Ltd. Primary endpoints: Adverse Events at 6 months and Systemic immune response at 6 months. Started Feb 2023; status: recruiting.
02
Drugs
R130
03
Conditions
Cervical Cancer (CC)endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05812677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05812677.